Simple blood and urine test could spot bladder cancer return
NCT ID NCT07441499
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new liquid biopsy that uses blood and urine samples to help diagnose, monitor treatment, and predict recurrence in people with urothelial carcinoma (a type of bladder cancer). Researchers will enroll 300 participants and compare the liquid biopsy results with standard tissue biopsies. The goal is to see if this non-invasive test can reliably track cancer changes over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Multi-component liquid biopsy (blood and urine test)
What this could lead to
If successful, this could provide a non-invasive way to detect and monitor urothelial cancer, potentially reducing the need for repeated tissue biopsies.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The test may not be accurate enough to replace standard biopsy, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The second hospital of Tianjin Medical University
RECRUITINGTianjin, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••